GlassScriptPhysician profile
Steven Ray Evans
NPI 1417064718
$7,518.35
in general payments reported to CMS, 2019-2025
24 companies · $1,710 in 2025
The $1,710 reported for 2025 was more than what 91% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $561 · 2022: $1,604 · 2023: $1,624 · 2024: $2,019 · 2025: $1,710.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,029 · Education: $324.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,028.65 |
| Education | $323.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,451.00 | 2021-2023 | Opticross, Wolverine Coronary Cutting Balloon, Rotapro |
| Abbvie INC. | $1,242.26 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $965.12 | 2021-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $545.63 | 2021-2025 | Tremfya |
| Pfizer INC. | $406.47 | 2022-2025 | |
| Ucb, INC. | $382.17 | 2023-2025 | Bimzelx, Cimzia |
| Genzyme Corporation | $362.41 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $284.39 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $262.52 | 2023-2025 | Sotyktu |
| Dermavant Sciences, INC. | $258.63 | 2023-2024 | Vtama |
| Incyte Corporation | $206.72 | 2021-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $205.31 | 2022-2025 | |
| Lilly USA, LLC | $160.64 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Amgen INC. | $127.18 | 2024-2025 | Otezla, Otezla |
| Arcutis Biotherapeutics, INC. | $109.77 | 2023-2025 | Zoryve |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $109.14 | 2022-2024 | Spevigo |
| Hill Dermaceuticals, INC. | $108.46 | 2025 | Tolak |
| Organon LLC | $102.40 | 2025 | Vtama |
| Leo Pharma INC. | $48.55 | 2022-2023 | Adbry |
| Galderma Laboratories, L.P. | $47.75 | 2023-2025 | Nemluvio, Aklief, Oracea |
| Edwards Lifesciences Corporation | $40.97 | 2023-2024 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Verrica Pharmaceuticals INC. | $34.98 | 2023 | Ycanth |
| Almirall LLC | $32.30 | 2022 | |
| Glaxosmithkline, LLC. | $23.58 | 2025 | Shingrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.